



Universiteit
Leiden
The Netherlands

New approaches to imaging and treatment of ocular melanoma

Brouwer, N.J.

Citation

Brouwer, N. J. (2022, April 13). *New approaches to imaging and treatment of ocular melanoma*. Retrieved from <https://hdl.handle.net/1887/3283451>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3283451>

Note: To cite this publication please use the final published version (if applicable).

**NEW APPROACHES TO
IMAGING AND TREATMENT
OF OCULAR MELANOMA**

Niels Johan Brouwer

New approaches to imaging and treatment of ocular melanoma

Thesis, Leiden University, The Netherlands

Author: Niels Brouwer
ISBN: 978-94-93108-32-5
Cover design: James Jardine | www.jamesjardine.nl
Layout: James Jardine | www.jamesjardine.nl
Printing: Ridderprint | www.ridderprint.nl

The research described in this thesis was financially supported by

MD/PhD-programme grant (Leiden University Medical Center), European Commission Horizon 2020 program UM Cure (Project number: 667787), China Scholarship Council (JC), Dutch Cancer Society funding (UL 2013-5757), Uveal Melanoma Bontius Fund, Stichting Leids Oogheelkundig Ondersteuningsfonds (LOOF), Stichting Nelly Reef Fund, Foundation “De Drie Lichten”, Stichting Blindenhulp, Stichting tot Verbetering van het Lot der Blinden, Rotterdamse Stichting Blindenbelangen, Landelijke Stichting voor Blinden en Slechthzienden (LSBS), Stichting PG Binkhorst, Leids Universiteits Fonds / P.A. Jager-van Gelder Fonds, Algemene Nederlandse Vereniging Ter Voorkoming van Blindheid (ANVVB), Stichting Blinden Penning, Novartis Foundation, Stichting Nederlands Oogheelkundig Onderzoek (SNOO), Mr. O. Roell (Oxymap T1 device), Laméris Ootech BV (Nidek OCTA device)

Financial support for the printing of this thesis was kindly provided by

Stichting LOOF, Landelijke Stichting voor Blinden en Slechthzienden (LSBS), Stichting Blindenhulp, Stichting tot Verbetering van het Lot der Blinden, Rotterdamse Stichting Blindenbelangen, Bayer, Chipsoft, Horus Pharma BV, Low Vision Totaal, Rockmed BV, Santen Pharmaceutical Co. Ltd, Synga Medical, Théa Pharma BV, Tramedico, Vitaminen op Recept

All funding organisations provided unrestricted grants and had no role in the design or conduct of this research.

© Niels Johan Brouwer, 2022 (nielsj.brouwer@hotmail.com). All rights reserved. No part of this thesis may be reproduced in any form without written permission from the author.

NEW APPROACHES TO IMAGING AND TREATMENT OF OCULAR MELANOMA

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op woensdag 13 april 2022
klokke 15.00 uur

door

Niels Johan Brouwer

Geboren te 's-Gravenhage

In 1990

Promotoren

Prof. dr. M.J. Jager

Prof. dr. G.P.M. Luyten

Promotiecommissie

Prof. dr. N.E. Schalijs-Delfos

Prof. dr. S. Heegaard

Prof. dr. L.M. Heindl

Dr. N.C. Naus

Prof. dr. D.G. Vavvas

University of Copenhagen, Denmark

University of Cologne, Germany

Erasmus University Medical Center, The Netherlands

Massachusetts Eye and Ear Infirmary / Harvard University, USA

**“Alles wat teveel is,
is strijdig met de natuur”**

(Hippocrates van Kos, ca 460-370 v Chr.)

Voor mijn ouders

Contents

Background

1	General Introduction and Outline of Thesis	11
---	--	----

PART I: Conjunctival Melanoma

2	Current Treatments	
2.1	Treatment of Conjunctival Melanoma in a Dutch Referral Centre <i>Br J Ophthalmol</i> 2018; 102(9):1277-1282	33
2.2	Lack of Tumour Pigmentation in Conjunctival Melanoma is Associated with Light Iris Colour and Worse Prognosis <i>Br J Ophthalmol</i> 2019; 103(3):332-337	49
2.3	Pigmentation of Conjunctival Melanoma Recurrences and Outcome <i>Graefes Arch Clin Exp Ophthalmol</i> 2019; 257(8):1783-1788	67
3	Treatment Targets	
3.1	Conjunctival Melanoma: New Insights in Tumour Genetics and Immunology leading to New Therapeutic Options <i>Progress in Ret Eye Res</i> 2022; 86:100971	81
3.2	PD-L1/PD-1 Expression and Tumor-Infiltrating Lymphocytes in Conjunctival Melanoma <i>Oncotarget</i> 2017; 8(33):54722-54734	169

PART II: Uveal Melanoma

4	Treatment Targets	
4.1	Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma with Verteporfin <i>Invest Ophthalmol Vis Sci</i> 2021; 62(4):3	197
4.2	Tumour Angiogenesis in Uveal Melanoma Is Related to Genetic Evolution <i>Cancers (Basel)</i> 2019; 11(7). pii: E979	227
5	Imaging Techniques	
5.1	Retinal Oximetry is Altered in Eyes with Choroidal Melanoma but not in Eyes with Choroidal Nevi <i>Retina</i> 2020; 40(11):2207-2215	251
5.2	Anterior Segment OCTA of Melanocytic Lesions of the Conjunctiva and Iris <i>Am J Ophthalmol</i> 2020; 222:137-147	273

Clinical cases

6 Clinical Cases

- | | | |
|-----|--|-----|
| 6.1 | Conjunctival Metastasis of a Cutaneous Melanoma | 297 |
| | <i>Ocul Oncol Pathol 2018; 4(2):107-111</i> | |
| 6.2 | Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma | 307 |
| | <i>Ocul Oncol Pathol 2017; 3(3):188-192</i> | |
| 6.3 | Two Late Recurrences of Conjunctival Melanoma | 317 |
| | <i>Ocul Oncol Pathol 2019; 5(4):262-266</i> | |
| 6.4 | Multiple Pigmented Conjunctival Lesions following Intravitreal Injections in a Patient with Uveal Melanoma | 327 |
| | <i>Ocul Oncol Pathol 2017; 3(2):113-116</i> | |

General Discussion and Appendices

7 Summary and General Discussion 337

8 Appendices

- | | | |
|-----|----------------------|-----|
| 8.1 | Dutch Summary | 355 |
| 8.2 | Acknowledgements | 369 |
| 8.3 | Curriculum Vitae | 373 |
| 8.4 | List of Publications | 375 |